Claris rais­es $57M in Se­ries A as it awaits key tri­al read­out on eye drug

Claris an­nounced a $57 mil­lion Se­ries A on Thurs­day morn­ing as it launched from stealth. The Jer­sey City biotech is work­ing on an eye drug based on in­ves­ti­ga­tions by Har­vard re­searchers.

The treat­ment is a so­lu­tion of re­com­bi­nant hu­man vari­ant he­pa­to­cyte growth fac­tor, or dHGF, which Claris be­lieves can “ac­cel­er­ate and im­prove” heal­ing of the cornea, the out­er­most clear tis­sue cov­er­ing the front of the eye.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER